Lorlatinib has 4 known drug interactions based on U.S. FDA drug labeling data. Of these, 2 are contraindicated combinations that should be avoided entirely. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Cyp3a Inducers, Rifampin, Fluconazole. Patients taking Lorlatinib should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 4
- Contraindicated
- 2
- Major
- 2
Contraindicated (2)
- Lorlatinib + Cyp3a Inducers— Strong CYP3A inducers are contraindicated with lorlatinib. Concomitant use decreases lorlatinib plasma concentrations, w…
- Lorlatinib + Rifampin— Severe hepatotoxicity occurred in healthy subjects receiving lorlatinib with rifampin (a strong CYP3A inducer). Grade 3-…
Major (2)
- Lorlatinib + Fluconazole— ( 2.4 , 7.1 ) • Fluconazole : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. Fluconaz…
- Lorlatinib + Mao Inhibitors— Avoid concomitant use with strong CYP3A inhibitors; reduce lorlatinib dose if unavoidable. Increases lorlatinib plasma c…